trending Market Intelligence /marketintelligence/en/news-insights/trending/zVOaBSdL5VrMQc5d21zzIQ2 content esgSubNav
In This List

Galena Biopharma stockholders approve merger with SELLAS Life Sciences

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Galena Biopharma stockholders approve merger with SELLAS Life Sciences

Galena Biopharma Inc. stockholders approved all proposals necessary for the company's merger agreement with Switzerland-based SELLAS Life Sciences Group Ltd.

The stockholders also approved a reverse stock split of Galena common shares at a ratio of not less than 1-for-10 and not greater than 1-for-30.

Galena's board has determined and SELLAS has agreed to effect the reverse stock split of the Galena common stock at a ratio of 1-for-30.

The reverse stock split is expected to become effective at 4:15 p.m. ET on Dec. 29. The merger is expected to close shortly after the effectiveness of the reverse stock split.

The combined company will be renamed SELLAS Life Sciences Group Inc. and will commence trading on the Nasdaq Capital Market on a post-reverse stock split basis under the new symbol SLS from Jan. 2, 2018.